Gerry Gleeson

Bio:

Gerry Gleeson is a recognized industry leader in large-/small-molecule, specialty, biologics, oncology and vaccine therapeutic areas across numerous market access and trade business channels. He is known for his skill and success in building highly productive teams with deep emphasis on developing organizational leaders that excel in critical action-oriented behaviors that fuel business growth. He has significant US pricing and policy expertise, specifically in the areas related to the Inflation Reduction Act. 

Gerry led the market access launch and pricing strategy for several specialty and general medicines portfolios which generated sales of more than $10B annually. He transformed the negotiations and business relationship with top wholesaler/specialty distributor organizations in the US to ensure
on-time distribution of ~$20B in annual US sales. He also launched an innovative patient support management program, which yielded an estimated $300M in annual savings for the business unit.

Gerry is currently the Vice President of Market Access, Trade and Patient Services for Amneal.  In this leadership position,  Gerry spearheads negotiations with large scale payers, PBMs, GPOs, and wholesalers, along with national account management team to secure profitable access for the US product portfolio for Specialty and Biosimilar assets.  In addition, Gerry is tasked with building a best-in-class patient support organization to improve access and affordability.

Prior to Amneal, Gerry was Head of US Market Access & Wholesale Trade at Sanofi, a global biopharmaceutical company.  At Sanofi, he revamped the specialty product distribution strategy for immunology and oncology portfolios, yielding $100M in increased profitability and he led strategic pricing efforts for US launch and in-line brands for pre- and post-IRA implementation/impacts to revise the pricing and revenue forecasts for each US brand.

Previously, at Walgreens, an integrated healthcare, retail, and specialty pharmacy, Gerry guided the  organization in becoming the third-largest US Specialty Pharmacy in revenue and covered lives by transforming the go-to-market model to focus on acquiring new business and streamlining operating expenses. He forged strategic business partnerships with biopharmaceutical manufacturers across all core segments, leading to a $75M increase in retail and specialty sales. He developed the business entity for the Walgreens Clinical Trial Program, collaborating with biopharmaceutical manufacturers to execute localized clinical trials using the Walgreens community network to build a new business division.

Earlier in his career Gerry held leadership positions a Merck, KMPC Peat Marwick LLP, and New York Life Health Care Plans.   Gerry holds an MBA in Healthcare Administration & Finance from Temple University and a BA in Political Science from Villanova University both located in Philadelphia, PA. He has previously served as a board member at Option Care, CareMetx, and the National Association of Specialty Pharmacy.